Companies · Other Health Care

VentureMed Group, Inc.

PLYMOUTH · Other Health Care

Diligence memoA one-page analyst read on VentureMed Group, Inc. — recommendation, valuation, rhythm, risks.
$59.8M
Total raised · real
5
Rounds
24.6×
Latest step-up
Top 8%
Sector rank · raised
Series C
Latest stage · inferred · Fri Oct 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

VentureMed Group, Inc. looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.27× the median modeled value of Series C Other Health Care companies in 2025–2027 (20 peers) — value vs value, same stage and era.
  • Within the normal band (127% of peer median) for its niche.
Active
  • Last raise 8 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

VentureMed Group, Inc. is one of 5376 Other Health Care companies tracked from PLYMOUTH. By capital raised it ranks among the largest (ahead of 93% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2
Investors (latest)
2025-10-17
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeed · 2019-06-03 Raised $1.0M (real) Modeled valuation $26M (est)$1.0M$26MSeed2019Seed · 2022-12-21 Raised $588K (real) Modeled valuation $5.0M (est)$588K$5.0MSeed2022Seed · 2023-12-21 Raised $2.0M (real) Modeled valuation $11M (est)$2.0M$11MSeed2023Series A · 2024-10-31 Raised $7.0M (real) Modeled valuation $30M (est)$7.0M$30MSeries A2024Seed · 2024-10-31 Raised $2.0M (real) Modeled valuation $7.7M (est)$2.0M$7.7MSeed2024Series C · 2025-10-17 Raised $49M (real) Modeled valuation $288M (est)$49M$288MSeries C2025+$588K+$2.0M+$7.0M+$2.0M+$49MCumulative $62M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.0M · 2019
Seed extension$588K · 2022
Seed extension$2.0M · 2023
Series A$7.0M · 2024
Bridge · Series A-stage$2.0M · 2024smaller follow-on
Series C$49.2M · 2025no Series B on file

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 60%.

Modeled valuation trajectory
$288.0M
Base estimate est.
$178.7M
Conservative case
$366.1M
Upside case
$327.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $25.9M · 2019-06-032019Seed · modeled $5.0M · 2022-12-21Seed · modeled $11.1M · 2023-12-21Series A · modeled $29.9M · 2024-10-31Seed · modeled $7.7M · 2024-10-31Series C · modeled $288.0M · 2025-10-172025
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
0.7 yr
Elapsed time used
0.7 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
15 mo
Avg between rounds
$9.4M/yr
Capital velocity
7.1 yr
On record since
2019
First round
6
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 25× above median
This company$59.8M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.1× above median
This company$49.2M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 13× above median
This company$288.0M
Sector median$22.1M

Raised more than 93% of sector peers (real $). Modeled value above 90% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #7 of 20.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)RESTOR3D, Inc. · Series C Raised $239.2M · modeled $522.0M (est)ByHeart, Inc. · Series C Raised $378.4M · modeled $493.2M (est)SpyGlassPharma, Inc. · Series C Raised $134.8M · modeled $484.8M (est)VantAI Holdings, Inc. · Series C Raised $86.3M · modeled $475.3M (est)BioIntelliSense, Inc. · Series C Raised $140.0M · modeled $328.7M (est)ObjectiveHealth, Inc. · Series C Raised $68.0M · modeled $321.0M (est)Exo Imaging, Inc. · Series C Raised $169.6M · modeled $284.4M (est)InspireMD, Inc. · Series C Raised $117.2M · modeled $248.1M (est)Fonar, Llc · Series C Raised $51.2M · modeled $228.9M (est)MicroTransponder, Inc. · Series C Raised $117.7M · modeled $223.2M (est)Fourth Edge LLC · Series C Raised $119.7M · modeled $221.8M (est)VentureMed Group, Inc. (this company) Raised $59.8M · modeled $288.0M (est)VentureMed Group, Inc.
CompanyStageRaised · realValue · estvs peer med.
RESTOR3D, Inc.Series C$239.2M$522.0M2.31×
ByHeart, Inc.Series C$378.4M$493.2M2.18×
SpyGlassPharma, Inc.Series C$134.8M$484.8M2.14×
VantAI Holdings, Inc.Series C$86.3M$475.3M2.10×
BioIntelliSense, Inc.Series C$140.0M$328.7M1.45×
ObjectiveHealth, Inc.Series C$68.0M$321.0M1.42×
VentureMed Group, Inc. this companySeries C$59.8M$288.0M1.27×
Exo Imaging, Inc.Series C$169.6M$284.4M1.26×
InspireMD, Inc.Series C$117.2M$248.1M1.10×
Fonar, LlcSeries C$51.2M$228.9M1.01×
MicroTransponder, Inc.Series C$117.7M$223.2M0.99×
Fourth Edge LLCSeries C$119.7M$221.8M0.98×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.0M2019-06-03$5.2M$25.9M90%
Seed$588K2022-12-21$2.9M$5.0M90%
Seed$2.0M2023-12-21$10.0M$11.1M90%
Series A$7.0M2024-10-31$31.8M$29.9M90%
Seed$2.0M2024-10-31$10.0M$7.7M90%
Series C$49.2M2025-10-17$327.8M$288.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.0M2019-06-03
    • First recorded raise — entered as Seed.
    • 2 investors on this round.
  2. Seed$588K2022-12-21
    • Raised again after 43 mo — slower than the ~14 mo sector norm.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  3. Seed$2.0M2023-12-21
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 3.4× larger than the prior — scaling up.
    • 3 investors on this round.
  4. Series A$7.0M2024-10-31
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 3.5× larger than the prior — scaling up.
    • 1 investor on this round.
  5. Seed$2.0M2024-10-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  6. Series C$49.2M2025-10-17
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 24.6× larger than the prior — scaling up.
    • 2 investors on this round.
Intelligence
2027 ~Q1
Modeled next raise · ~15mo cadence
$147.5M
Modeled next size est.range $95.9M$236.0M
24.6×
Last step-up
$9.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Denis Harrington2 other2022-12
J. Robert Paulson, Jr.2 other2019-06
Alexander Robert Schmitz2019-06
Brian Robert Smith2025-10
Dave Robert Michaelson2022-12
David Robert Cox2019-06
Jacques Robert Essinger2025-10
Jenny Robert Zeroni2019-06
Jill Robert Schweiger2019-06
John Robert Pigott2019-06
Karen Robert Spilizewski2019-06
Kathy Robert Leith2024-10
Shelby Robert Hautman2019-06
Registry & provenance

VentureMed Group, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1552080
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
TW-NHME Holdings Corp.Other Health CareSeries C$64.3M$171.5Msame sector · same stage
Dental Implant Holdings, LLCOther Health CareSeries C$53.7M$228.6Msame sector · same stage
ObjectiveHealth, Inc.Other Health CareSeries C$68.0M$321.0Msame sector · same stage
Calypso Medical Technologies IncOther Health CareSeries C$69.5M$171.5Msame sector · same stage
Fonar, LlcOther Health CareSeries C$51.2M$228.9Msame sector · same stage
Forentis Fund, LPOther Health CareSeries C$50.0M$244.4Msame sector · same stage
Healthcare Ventures Fund IV, LPOther Health CareSeries C$50.0M$244.4Msame sector · same stage
Cytrellis Biosystems, Inc.Other Health CareSeries C$82.7M$182.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
PAVmed Inc.Other Health CareSeries B$120.6M87%
VVV Capital International LLPOther Health CareSeed$83.7M86%
Vtm, LlcOther Health CareSeed$3.7M86%
BioMedx Group, Inc.Other Health CarePre-Seed$14.0M86%
VentureCare Partners Inc.Other TechnologyPre-Seed$1.2M85%
AVG Holdings, Inc.Other Health CareSeries A$282.5M85%
Vymedic Inc.Other Health CareSeed$10.3M84%
Vyvve, LLCOther Health CareSeed$26.5M84%
Frequently asked
How much funding has VentureMed Group, Inc. raised?
VentureMed Group, Inc. has raised approximately $59.8M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is VentureMed Group, Inc.'s estimated valuation?
Provath's modeled valuation for VentureMed Group, Inc. is approximately $288.0M (modeled range $178.7M–$366.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is VentureMed Group, Inc. at?
VentureMed Group, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Fri Oct 17.
What does VentureMed Group, Inc. do and where is it based?
VentureMed Group, Inc. operates in the Other Health Care sector, based in PLYMOUTH.
Explore related

See where VentureMed Group, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at VentureMed Group, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.